Cambridge Healthtech Institute’s 2nd Annual
Engineering Antibody-Drug Conjugates
Designing the Magic Bullet
12 November 2025
Cambridge Healthtech Institute’s 2nd Annual Engineering Antibody-Drug Conjugates conference showcases state-of-the-art innovations in bispecific ADC platforms, novel payloads and mechanisms of action, next-generation conjugation technologies such as radioimmunoconjugates, and oligo-, peptide-, and immunocytokine-conjugated ADCs. The conference will also look beyond oncology, delivering ADCs for autoimmune and infectious diseases. Join leading researchers and industry innovators in driving these targeted therapies toward clinical success.
Coverage will include, but is not limited to:
Bispecific ADCs
- Dual-targeting strategies
- Improved tumour penetration
- Overcoming resistance mechanisms
- Format considerations for multispecific ADCs
Expanding ADC Applications
- ADCs beyond oncology: applications in autoimmune and infectious diseases
- Radioimmunoconjugates
- Oligonucleotide- and peptide-conjugated ADCs
- Cytokine-conjugated antibodies
Next-Generation ADC Payloads and MOAs
- Beyond cytotoxics: novel payload classes
- Dual-payload strategies
- Immune-modulating payloads
- Payload innovations for improved therapeutic index
- Degrader-based ADCs
Novel Linker Technologies
- Site-specific conjugation strategies
- Cleavable vs. non-cleavable linkers
- Payload-release mechanisms
- Linker designs for improved stability
The deadline for priority consideration is 28 March 2025.
All proposals are subject to review by session chairpersons and/or the Scientific Advisory Committee to ensure the overall quality of the conference program. Additionally, as per Cambridge Healthtech Institute’s policy, a select number of vendors and consultants who provide products and services will be offered opportunities for podium presentation slots based on a variety of Corporate Sponsorships.
Opportunities for Participation: